Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Discovery of a dual inhibitor of NQO1 and GSTP1 for treating glioblastoma

Fig. 1

Identification of MNPC via ultra-high-throughput screen (uHTS) assay for U87MG/EGFRvIII versus U87MG cells. a Miniaturized uHTS cell viability assay development for selectively blocking U87MG/EGFRvIII versus U87MG cells. b The chemical structure and 3D alignment of the structure of MNPC. c Effect of MNPC (0, 0.3125, 0.625, 1.25, 2.5, 5 μM for 72 h) on the proliferation of U87MG/EGFRvIII and U87MG cells. Data are mean ± SD from three replicates, p values were determined by a two-tailed Student’s t test (*p < 0.05; **p < 0.01; ***p < 0.001). d The SAR analysis of MNPC. The structures and IC50 of inhibition activity of the compound derivatives in U87MG/EGFRvIII and U87MG cells. eg MNPC dose-dependently blocks primary GBM sphere formation capacity. Primary GBM cells with EGFRvIII mutations were cultured with two doses of MNPC and plated for limiting dilution analysis. The formation of spheres (shown in e) was assessed for all wells and used to generate stem cell frequencies (f, g). Scale bar: 100 μm

Back to article page